Annexon hosts virtual investor event on Phase 3 ARCHER II trial

ANNX•2026-10-28

Annexon will host a virtual investor event on Nov. 3, 2026, at 11 a.m. ET, focused on the Phase 3 ARCHER II trial of vonaprument for geographic atrophy.

1. Investor event

Presentations will cover the trial’s design and patient demographics.

Annexon hosts virtual investor event on Phase 3 ARCHER II trial

1. Investor event

Related News

Nuburu faces October 29 deadline for NYSE American equity compliance

Evolution Metals & Technologies confirms delivery of all 57 Ulvac equipment containers to Pohang expansion site

GM moves to Nasdaq as first legacy automaker on the exchange

IHG signs first Garner hotel in Uzbekistan, with 100 rooms planned for 2027 opening

Evolus participates in Stifel and Jefferies healthcare conferences